サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：リウマチ治療薬の世界市場：2023-2030年
市場調査レポート
商品コード
1351027

リウマチ治療薬の世界市場：2023-2030年

Global Rheumatology Therapeutics Market 2023-2030
出版日: | 発行: Orion Market Research | ページ情報: 英文 145 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
リウマチ治療薬の世界市場：2023-2030年
出版日: 2023年09月06日
発行: Orion Market Research
ページ情報: 英文 145 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界市場は予測期間（2023-2030年）にCAGR 3.2％で成長すると予測されています。治療薬は、関節リウマチ（RA）などの特定の自己免疫性リウマチ性疾患の進行を遅らせるために使用されます。RAの世界の有病率の増加が新規治療薬の発売を後押ししており、高コストの治療薬に対する有利な改修政策も市場成長を促進する要因の一つです。米国国立衛生研究所（NIH）によると、2023年5月の時点で、関節リウマチの生涯リスクは男性1.7％に対し女性3.6％と、男性に比べ女性の方が多くなっています。また、RAリスクは年齢とともに増加し、65歳から80歳の間に発症のピークを迎えます。さらに、新規生物学的製剤の上市率の上昇、承認の増加、ジェネリック医薬品の浸透の拡大は、リウマチ治療薬市場に有益な機会を広げています。例えば、アムジェンは2022年6月、リツキサン（R）のバイオシミラーであるRIABNI（TM）（rituximab-arrx）を、1種類以上の腫瘍壊死因子（TNF）拮抗薬による治療で効果が不十分な中等度から重度の活動性の関節リウマチ（RA）の成人患者を対象に、メトトレキサートとの併用でFDAが承認したと発表しました。

セグメント別の展望

疾患修飾性抗リウマチ薬（DMARDs）サブセグメントが世界のリウマチ治療薬市場で大きなシェアを占めると予想される

薬剤の種類別では、DMARDsサブセグメントが世界のリウマチ治療薬市場で大きなシェアを占めると予想されます。同分野の成長は、世界のRA発症率の上昇と相まってDMARDの利用が増加していることに起因しています。例えば、National Center for Biotechnology Informationによると、2022年6月現在、米国および他の西欧諸国（北欧）におけるRAの年間発症率は10万人当たり約40人です。RAに対する治療オプションに対する認識が高まっているためです。

地域別展望

世界のリウマチ治療薬市場は、北米（米国、カナダ）、欧州（英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域）、アジア太平洋地域（インド、中国、日本、韓国、その他アジア地域）、世界のその他の地域（中東とアフリカ、中南米）を含む地域別にさらに細分化されています。このうち、アジア太平洋地域は、関節リウマチの有病率の増加、疾患に関する認知度の向上、および先進的な関節リウマチ治療薬の採用と組み合わせた有病率の増加により、市場の成長を促進すると予想されるため、市場で突出したシェアを占めると予想されます。主な市場プレイヤーには、中外製薬株式会社、Dr Reddy's Laboratories Ltd.、LG Chem、Lupin Ltd.、LG Chem, Inc.LG Chem社、Lupin Ltd社、大正製薬ホールディングス株式会社などが含まれます。

北米地域は世界のリウマチ治療薬市場で大きなCAGRで成長する見込み

全地域の中で、北米地域は予測期間中にかなりのCAGRで成長すると予測されています。同地域の市場成長は、リウマチ性疾患の早期診断と治療に関する意識の高まりと、治療におけるDMARDsの使用の増加に起因しています。さらに、新規生物学的製剤の上市の増加、承認の増加、ジェネリック医薬品の浸透の拡大は、リウマチ治療薬市場のプレーヤーに有益な機会を広げています。例えば、2023年7月、Biocon Ltd.の子会社であるBiocon Biologics Ltd.（BBL）は、欧州で5年間、カナダで2年間使用された後、ヒュミラ（R）（アダリムマブ）のバイオシミラーであるヒュリオ（R）（アダリムマブ-fkjp）注射剤が米国で患者が使用できるようになったと発表しました。

目次

第1章 レポート概要

  • 業界の現状分析と成長ポテンシャルの展望
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • 推奨事項
    • 結論

第3章 競合情勢

  • 主要企業分析
  • Merck & Co., Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Novartis AG
    • 会社概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Pfizer Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析

第4章 市場セグメンテーション

  • リウマチ治療薬の世界市場：薬剤タイプ別
    • 疾患修飾性抗リウマチ薬
    • 非ステロイド性抗炎症薬
    • 副腎皮質ステロイド薬
    • 尿酸薬
    • その他
  • リウマチ治療薬の世界市場：適応疾患別
    • 関節リウマチ
    • 変形性関節症
    • 痛風
    • 乾癬性関節炎
    • 強直性脊椎炎
  • リウマチ治療薬の世界市場：カテゴリー別
    • 処方薬
    • 一般用医薬品（OTC）
  • リウマチ治療薬の世界市場：流通経路別
    • 病院薬局
    • 小売薬局
    • オンライン薬局

第5章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 世界のその他の地域

第6章 企業プロファイル

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Aurinia Pharmaceuticals Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • Eli Lilly
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Johnson & Johnson Private Ltd.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi, Genentech, Inc.
  • Takeda Pharmaceutical Company Ltd.
  • UCB S.A.
図表

LIST OF TABLES

  • 1. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL CORTICOSTEROIDS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL URIC ACID DRUGS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2022-2030 ($ MILLION)
  • 7. GLOBAL RHEUMATOID ARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL GOUT THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL PSORIATIC ARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL ANKYLOSING SPONDYLITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 13. GLOBAL RHEUMATOLOGY THERAPEUTICS BY PRESCRIPTION MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL RHEUMATOLOGY THERAPEUTICS BY OVER-THE-COUNTER (OTC) MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 16. GLOBAL RHEUMATOLOGY THERAPEUTICS IN HOSPITAL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 17. GLOBAL RHEUMATOLOGY THERAPEUTICS IN RETAIL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 18. GLOBAL RHEUMATOLOGY THERAPEUTICS IN ONLINE PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 19. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. NORTH AMERICAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 22. NORTH AMERICAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2022-2030 ($ MILLION)
  • 23. NORTH AMERICAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 24. NORTH AMERICAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 25. EUROPEAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 26. EUROPEAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 27. EUROPEAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2022-2030 ($ MILLION)
  • 28. EUROPEAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 29. EUROPEAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 30. ASIA- PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 31. ASIA- PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 32. ASIA- PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2022-2030 ($ MILLION)
  • 33. ASIA- PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 34. ASIA- PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 35. REST OF THE WORLD RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 36. REST OF THE WORLD RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 37. REST OF THE WORLD RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2022-2030 ($ MILLION)
  • 38. REST OF THE WORLD RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 39. REST OF THE WORLD RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL CORTICOSTEROIDS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL URIC ACID DRUGS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2022 VS 2030 (%)
  • 7. GLOBAL RHEUMATOID ARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL GOUT THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL PSORIATIC ARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL ANKYLOSING SPONDYLITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022 VS 2030 (%)
  • 13. GLOBAL RHEUMATOLOGY THERAPEUTICS BY PRESCRIPTION MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL RHEUMATOLOGY THERAPEUTICS BY OVER-THE-COUNTER (OTC) MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
  • 16. GLOBAL RHEUMATOLOGY THERAPEUTICS IN HOSPITAL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 17. GLOBAL RHEUMATOLOGY THERAPEUTICS IN RETAIL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 18. GLOBAL RHEUMATOLOGY THERAPEUTICS IN ONLINE PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 19. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 20. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 21. US RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. UK RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. REST OF EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 31. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 32. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 33. REST OF ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 34. REST OF THE WORLD RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
目次
Product Code: OMR2027627

Title: Global Rheumatology Therapeutics Market Size, Share & Trends Analysis Report by Drug Type (Disease-modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs and Others), by Disease Indication (Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, and Ankylosing Spondylitis), by Category (Prescription and Over-the-Counter (OTC), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy),Forecast Period (2023-2030).

The global market is anticipated to grow at a CAGR of 3.2% during the forecast period (2023-2030). Therapeutic drugs are used to slow down the progression of certain autoimmune rheumatic diseases such as rheumatic arthritis (RA). The increasing prevalence of RA globally has bolstered the launch of novel therapeutic agents and favorable refurbishment policies for high-cost treatment products are some of the factors driving the market growth. According to the National Institute of Health (NIH), in May 2023, rheumatic arthritis is more prevalent in women compared to men, with a lifetime risk of rheumatic arthritis of 3.6% in women compared to 1.7% in men. RA risk also increases with age, with a peak incidence between age 65 to 80 years of age. Furthermore, the rise in the rate of launches of novel biologics drugs, increasing approvals and growing penetration of generic drugs extend profitable opportunities to the rheumatology therapeutics market. For instance, in June 2022, Amgen announced that FDA approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

Segmental Outlook

The global rheumatology therapeutics market is segmented on the drug type, disease indication, category, and distribution channel. Based on the drug type, the market is sub-segmented into disease-modifying anti-rheumatic drugs, nonsteroidal anti-inflammatory drugs, corticosteroids, uric acid drugs and others. Based on the disease indication, the market is sub-segmented into rheumatoid arthritis, osteoarthritis, gout, psoriatic arthritis, and ankylosing spondylitis. Based on the category, the market is bifurcated into prescription and OTC. Furthermore, on the basis of distribution channel, the market is sub-segmented into hospital pharmacy, retail pharmacy and online pharmacy. Among the disease indication, the rheumatoid arthritis sub-segment is anticipated to hold a considerable share of the market owing to the development of novel technologies such as clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-based genome editing, RNA interference, PROTACs (proteolysis-targeted chimeras), and artificial intelligence (AI)-based drug design enable the screening of therapies targeting.

The Disease-modifying Anti-rheumatic Drugs (DMARDs) Sub-Segment is Anticipated to Hold a Considerable Share of the Global Rheumatology Therapeutics Market

Among the drug type, the sub-segment is expected to hold a considerable share of the global rheumatology therapeutics market. The segmental growth is attributed to the increased utilization of DMARD coupled with the rising incidence of RA around the globe. For instance, according to the National Center for Biotechnology Information, in June 2022, the annual incidence of RA in the US and other Western nations of northern Europe is about 40 per 100,000 persons. Owing to a surge in awareness related to treatment options available for RA.

Regional Outlook

The global rheumatology therapeutics market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, the Asia-Pacific region is anticipated to hold a prominent share of the market, owing to the increasing prevalence of rheumatoid arthritis, increasing awareness about the disorder, and increasing prevalence combined with the adoption of advanced rheumatoid arthritis therapeutics is expected to drive market growth. The key market player includes Chugai Pharmaceutical Co., Ltd., Dr Reddy's Laboratories Ltd. LG Chem, Lupin Ltd, Taisho Pharmaceutical Holdings Co., Ltd., and others.

The North America Region is Expected to Grow at a Significant CAGR in the Global Rheumatology Therapeutics Market

Among all regions, the North America region is anticipated to grow at a considerable CAGR over the forecast period. The regional market growth is attributed to the growing awareness regarding the early diagnosis and treatment of rheumatology disease and the increasing use of DMARD's for treating. Furthermore, the rise in launches of novel biologics drugs, increasing approvals and growing penetration of generic drugs extend profitable opportunities to the rheumatology therapeutics market players. For instance, in July 2023, Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd., announced that after 5 years of use in Europe and two years in Canada, HULIO® (adalimumab-fkjp) injectable, a biosimilar to Humira® (adalimumab), is now accessible to patients in the US.

Market Players Outlook

The major companies serving the global rheumatology therapeutics market include: F. Hoffmann-La Roche Ltd., Johnson & Johnson Private Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in January 2023, Gilead Sciences, Inc. and EVOQ Therapeutics, Inc. collaborated along with a licensing agreement to advance EVOQ's proprietary technology for the treatment of rheumatoid arthritis (RA) and lupus. EVOQ's NanoDisc technology is designed to enable lymph-targeted delivery of disease-specific antigens and has the potential to change the paradigm for the treatment of autoimmune diseases.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global rheumatology therapeutics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Merck & Co., Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Novartis AG
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Pfizer Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Rheumatology Therapeutics Market by Drug Type
    • 4.1.1. Disease-Modifying Anti-Rheumatic Drugs
    • 4.1.2. Non-Steroidal Anti-Inflammatory Drugs
    • 4.1.3. Corticosteroids
    • 4.1.4. Uric Acid Drugs
    • 4.1.5. Others
  • 4.2. Global Rheumatology Therapeutics Market by Disease Indication
    • 4.2.1. Rheumatoid Arthritis
    • 4.2.2. Osteoarthritis
    • 4.2.3. Gout
    • 4.2.4. Psoriatic Arthritis
    • 4.2.5. Ankylosing Spondylitis
  • 4.3. Global Rheumatology Therapeutics Market by Category
    • 4.3.1. Prescription
    • 4.3.2. Over-the-Counter (OTC)
  • 4.4. Global Rheumatology Therapeutics Market by Distribution Channel
    • 4.4.1. Hospital Pharmacy
    • 4.4.2. Retail Pharmacy
    • 4.4.3. Online Pharmacy

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. AbbVie Inc.
  • 6.2. Amgen Inc.
  • 6.3. AstraZeneca plc
  • 6.4. Aurinia Pharmaceuticals Inc.
  • 6.5. Boehringer Ingelheim International GmbH
  • 6.6. Bristol-Myers Squibb Co.
  • 6.7. Eli Lilly
  • 6.8. F. Hoffmann-La Roche Ltd.
  • 6.9. Gilead Sciences, Inc.
  • 6.10. Janssen Pharmaceuticals, Inc.
  • 6.11. Johnson & Johnson Private Ltd.
  • 6.12. Regeneron Pharmaceuticals Inc.
  • 6.13. Sanofi, Genentech, Inc.
  • 6.14. Takeda Pharmaceutical Company Ltd.
  • 6.15. UCB S.A.